Arterial HypertensionBLASTNCT04278001
Clinical Usefullness of the Cuffless SOMNOtouch NIBP Device for 24-hour Ambulatory Blood Pressure Measurement
A study testing Dual 24-hour ABPM in people with Arterial Hypertension, run by Central Jutland Regional Hospital at 1 site in Denmark.
Trial summary
The SOMNOtouch NIBP is a cuffless device for continuous blood pressure measurement. The device is widely used, but validation for 24-hour ambulatory blood pressure measurement (ABPM) is limited. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Arterial Hypertension
- What is being tested?
- Dual 24-hour ABPM
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Sep 2018to 1 Feb 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Indication for ABPM with an automated oscillometric device
Who cannot join
- Known significant arterial abnormalities in the upper extremities
- Known cardiac arrythmia
- Upper arm circumference >16,5" or <6", or
- Extreme uncontrolled hypertension (i.e. resting office BP > 230/140 mmHg).
Trial locations and contacts
1 site in 1 country.
About this study
The SOMNOtouch NIBP is a cuffless device for continuous blood pressure measurement. The device is widely used, but validation for 24-hour ambulatory blood pressure measurement (ABPM) is limited. This study seeks to validate the SOMNOtouch device for use in 24-hour ABMP as compared to a validated oscillometric device for 24-hour ABPM. A total of 60 patients with indication for 24-hour BP measurement will be recruited from our tertiary hypertension Clinic. All included patients will conduct dual 24-hour ABPM with both the SOMNOtouch NIBP and a the oscillometric device. Furthermore, patients will undergo measurement of arterial stiffness with a Sphygmocor device as well as complete a questionaire on device related discomfort.
Read the detailed description
Recruitment of study participants:
A total of 60 patients with indication for 24-hour BP measurement will be recruited from our tertiary hypertension clinic at Aarhus University Hospital, Aarhus, Denmark. Patients will be eligible for inclusion if they are 18 years or older and have indication for ABPM with an automated oscillometric device. Exclusion criteria will be as follows: Known significant arterial abnormalities in the upper extremities, known cardiac arrythmia, upper arm circumference >16,5" or <6", or extreme uncontrolled hypertension (i.e. resting office BP > 230/140 mmHg). To enable testing of the device at both normal and elevated BP-levels, we will aim at including at least 15 patients in each of the following categories: Normal BP, stage 1 hypertension and stage ≥2, based on NICE guidelines for ABPM17. Informed consent will obtained from all patients prior to inclusion in the study. At inclusion, a simultaneous bilateral BP-measurement will be performed with three consecutive measurements using an automated oscillometric device (Microlife WatchBP Office®) after 5 minutes of rest. If the difference in Systolic Blood Pressure (SBP) between the arms is found to be >5 mmHg, the patient will not be included in the study.
24-hour BP measurements: All staff related to the project are familiar with the SOMNOtouch NIBP™ (SomBP) device, which has been used in our clinic for selected patients with high cuff-based BP and at the same time symptoms of hypotension, since 2015. Mounting and calibration of both devices will be conducted according to manufacturers' instructions. With the patient sitting in an upright position with back-support, a conventional oscillometric BP-device (Spacelabs 90217 / 90207, OscBP) will be fitted on the right arm, while the SomBP will be fitted on the left arm. The SomBP will be calibrated with a single BP measurement with a cuff-based sphygmomanometer. The OscBP will record BP three times every hour during daytime and two times every hour during nighttime, while the SomBP will measure BP continuously. The patients will be instructed to engage in normal activities but refrain from strenuous exercise and, at the time of cuff-inflation, to stop moving and talking, while keeping the arm still with the cuff at heart level. Pulse wave velocity (PWV) as well as pulse wave analysis (PWA) will be performed in duplicate with the SphygmoCor system (version 8.2, Atcor Medical, Sydney, Australia). A small questionnaire on device-related pain and/or discomfort as well as sleeping habits will be provided to all participants. As per ESH guidelines, a minimum of 70% useful measurements on the oscillometric device during the ABPM will be required for the data to be considered useful. Assessment the acceptability of data-quality of SomBP will be made on the basis of discussion between the primary investigator and KLC, who, at the time of evaluation will both be blinded to the corresponding OscBP measurement. No SomBP measurements will be accepted with more than 50% failed measurement in the report. Data from both devices will be excluded from the study if data-collection from either device is deemed to have insufficient quality to be usable. For these instances, patients will be asked to repeat examination with both devices. SomBP1 data will extracted ad hoc using Domino Light 1.4.0 software.
Statistical analysis:
All statistical analysis will be performed using STATA software. A p-value of 0.05 will be prespecified as statistically significant. Variables will be checked for distribution through histograms and QQ-plots. Means will be compared using paired t-test. Standard regression analysis will be performed to test for association in continuous variables. Categorical variables will be compared using chi-squared tests.
- Conditions
- Arterial Hypertension
- Being tested
- Dual 24-hour ABPM
- Keywords
- Ambulatory blood pressure measurement
- Medical subject headings
- Hypertension
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dual 24-hour ABPMDevice
Dual 24-hour ABPM with both the SOMNOtouch NIBP and a validated oscillometric 24-hour ABPM-device (SPACELABS 90217 / 90207).
| Study group | Role | What they receive |
|---|---|---|
| Ambulatory blood pressure measurement | Other | Dual 24-hour ABPM with both the SOMNOtouch NIBP and a validated oscillometric 24-hour ABPM-device (SPACELABS 90217 / 90207). Receives: Device: Dual 24-hour ABPM |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference in blood pressure averages between SOMNOtouch NIBP and SPACELABS 90217 / 90207 during 24-hour ABPM
in mmHg
Measured: During 24-hour ABPM
Difference in mean systolic blood pressure between SOMNOtouch NIBP and SPACELABS 90217 / 90207 during 24-hour ABPM on the patient level
Bland Altman plots will be used to evaluate accuracy.
Measured: During 24-hour ABPM
Difference in mean diastolic blood pressure between SOMNOtouch NIBP and SPACELABS 90217 / 90207 during 24-hour ABPM on the patient level
Bland Altman plots will be used to evaluate accuracy.
Measured: During 24-hour ABPM
Secondary outcomes (3)
The impact of aortic augmentation index normalized to a Heart frequency of 75 beats/minute on BP Measurements with either device.
As measured using the SphygmoCor-device
Measured: Aortic augmentation index will be measured prior to 24-hour ABPM.
The impact of pulse wave velocity on BP Measurements with either device.
As measured using the SphygmoCor-device
Measured: Pulse Wave velocity will be measured prior to 24-hour ABPM.
Patient satisfaction with SOMNOtouch device compared with the oscillometric device.
As judged based on standardized questionaire.
Measured: Immediately after completion om 24-hour ABPM.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Feb 2020
- Study start1 Sep 2018
- Primary completion1 Feb 2020
- Study completion1 Feb 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Arterial HypertensionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Central Jutland Regional Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jakob Tobias Nyvad, Central Jutland Regional Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04278001
- Sponsor's protocol ID
- BLAST-AARHUS
- Acronym
- BLAST
- Status last verified
- Sep 2023
- First submitted
- 17 Feb 2020
- Last updated
- 2 Oct 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Nyvad J, Christensen KL, Buus NH, Reinhard M. The cuffless SOMNOtouch NIBP device shows poor agreement with a validated oscillometric device during 24-h ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2021 Jan;23(1):61-70. doi: 10.1111/jch.14135. Epub 2020 Dec 17.
PubMed 33350030
Study at a glance
From the registry record, last updated by the sponsor on 2 Oct 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Usefullness of the Cuffless SOMNOtouch NIBP Device for 24-hour Ambulatory Blood Pressure Measurement
- ClinicalTrials.gov ID
- NCT04278001
- Acronym / sponsor ID
- BLAST / BLAST-AARHUS
- Conditions
- Arterial Hypertension
- Keywords
- Ambulatory blood pressure measurement
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Central Jutland Regional HospitalUniversity, hospital or other
- Study start
- 1 Sep 2018 (actual)
- Primary completion
- 1 Feb 2020 (actual)
- Study completion
- 1 Feb 2020 (actual)
- First posted
- 20 Feb 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The SOMNOtouch NIBP is a cuffless device for continuous blood pressure measurement. The device is widely used, but validation for 24-hour ambulatory blood pressure measurement (ABPM) is limited. This study seeks to validate the SOMNOtouch device for use in 24-hour ABMP as compared to a validated oscillometric device for 24-hour ABPM. A total of 60 patients with indication for 24-hour BP measurement will be recruited from our tertiary hypertension Clinic. All included patients will conduct dual 24-hour ABPM with both the SOMNOtouch NIBP and a the oscillometric device. Furthermore, patients will undergo measurement of arterial stiffness with a Sphygmocor device as well as complete a questionaire on device related discomfort.
Detailed description
Recruitment of study participants:
A total of 60 patients with indication for 24-hour BP measurement will be recruited from our tertiary hypertension clinic at Aarhus University Hospital, Aarhus, Denmark. Patients will be eligible for inclusion if they are 18 years or older and have indication for ABPM with an automated oscillometric device. Exclusion criteria will be as follows: Known significant arterial abnormalities in the upper extremities, known cardiac arrythmia, upper arm circumference >16,5" or <6", or extreme uncontrolled hypertension (i.e. resting office BP > 230/140 mmHg). To enable testing of the device at both normal and elevated BP-levels, we will aim at including at least 15 patients in each of the following categories: Normal BP, stage 1 hypertension and stage ≥2, based on NICE guidelines for ABPM17. Informed consent will obtained from all patients prior to inclusion in the study. At inclusion, a simultaneous bilateral BP-measurement will be performed with three consecutive measurements using an automated oscillometric device (Microlife WatchBP Office®) after 5 minutes of rest. If the difference in Systolic Blood Pressure (SBP) between the arms is found to be >5 mmHg, the patient will not be included in the study.
24-hour BP measurements: All staff related to the project are familiar with the SOMNOtouch NIBP™ (SomBP) device, which has been used in our clinic for selected patients with high cuff-based BP and at the same time symptoms of hypotension, since 2015. Mounting and calibration of both devices will be conducted according to manufacturers' instructions. With the patient sitting in an upright position with back-support, a conventional oscillometric BP-device (Spacelabs 90217 / 90207, OscBP) will be fitted on the right arm, while the SomBP will be fitted on the left arm. The SomBP will be calibrated with a single BP measurement with a cuff-based sphygmomanometer. The OscBP will record BP three times every hour during daytime and two times every hour during nighttime, while the SomBP will measure BP continuously. The patients will be instructed to engage in normal activities but refrain from strenuous exercise and, at the time of cuff-inflation, to stop moving and talking, while keeping the arm still with the cuff at heart level. Pulse wave velocity (PWV) as well as pulse wave analysis (PWA) will be performed in duplicate with the SphygmoCor system (version 8.2, Atcor Medical, Sydney, Australia). A small questionnaire on device-related pain and/or discomfort as well as sleeping habits will be provided to all participants. As per ESH guidelines, a minimum of 70% useful measurements on the oscillometric device during the ABPM will be required for the data to be considered useful. Assessment the acceptability of data-quality of SomBP will be made on the basis of discussion between the primary investigator and KLC, who, at the time of evaluation will both be blinded to the corresponding OscBP measurement. No SomBP measurements will be accepted with more than 50% failed measurement in the report. Data from both devices will be excluded from the study if data-collection from either device is deemed to have insufficient quality to be usable. For these instances, patients will be asked to repeat examination with both devices. SomBP1 data will extracted ad hoc using Domino Light 1.4.0 software.
Statistical analysis:
All statistical analysis will be performed using STATA software. A p-value of 0.05 will be prespecified as statistically significant. Variables will be checked for distribution through histograms and QQ-plots. Means will be compared using paired t-test. Standard regression analysis will be performed to test for association in continuous variables. Categorical variables will be compared using chi-squared tests.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Ambulatory blood pressure measurement | Other | Device: Dual 24-hour ABPMDual 24-hour ABPM with both the SOMNOtouch NIBP and a validated oscillometric 24-hour ABPM-device (SPACELABS 90217 / 90207). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Indication for ABPM with an automated oscillometric device
Key exclusion criteria (4 listed)
- Known significant arterial abnormalities in the upper extremities
- Known cardiac arrythmia
- Upper arm circumference >16,5" or <6", or
- Extreme uncontrolled hypertension (i.e. resting office BP > 230/140 mmHg).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dual 24-hour ABPMDual 24-hour ABPM with both the SOMNOtouch NIBP and a validated oscillometric 24-hour ABPM-device (SPACELABS 90217 / 90207). | Device | Ambulatory blood pressure measurement |
Primary outcome
Difference in blood pressure averages between SOMNOtouch NIBP and SPACELABS 90217 / 90207 during 24-hour ABPM
Time frame: During 24-hour ABPM
in mmHg
Difference in mean systolic blood pressure between SOMNOtouch NIBP and SPACELABS 90217 / 90207 during 24-hour ABPM on the patient level
Time frame: During 24-hour ABPM
Bland Altman plots will be used to evaluate accuracy.
Difference in mean diastolic blood pressure between SOMNOtouch NIBP and SPACELABS 90217 / 90207 during 24-hour ABPM on the patient level
Time frame: During 24-hour ABPM
Bland Altman plots will be used to evaluate accuracy.
3 secondary outcomes
The impact of aortic augmentation index normalized to a Heart frequency of 75 beats/minute on BP Measurements with either device.
Time frame: Aortic augmentation index will be measured prior to 24-hour ABPM.
The impact of pulse wave velocity on BP Measurements with either device.
Time frame: Pulse Wave velocity will be measured prior to 24-hour ABPM.
Patient satisfaction with SOMNOtouch device compared with the oscillometric device.
Time frame: Immediately after completion om 24-hour ABPM.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Oct 2023.
- Derived from this study: PubMed 33350030Nyvad J, Christensen KL, Buus NH, Reinhard M. The cuffless SOMNOtouch NIBP device shows poor agreement with a validated oscillometric device during 24-h ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich). 2021 Jan;23(1):61-70. doi: 10.1111/jch.14135. Epub 2020 Dec 17.
- Individual participant dataSharing planned: Undecided
Related trials for Arterial Hypertension
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Recruiting
Trial Phase: Syndemic Adapted Medly Uganda
Mental Health
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Enrolling by invitation
Testing Implementation Strategies to Support Clinic Fidelity to an Outpatient Hypertension Bundle
Pregnancy Related, Hypertension
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dual 24-hour ABPM in people with Arterial Hypertension, run by Central Jutland Regional Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difference in blood pressure averages between SOMNOtouch NIBP and SPACELABS 90217 / 90207 during 24-hour ABPM (time frame: During 24-hour ABPM). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04278001, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Oct 2023; AzTrials last refreshed its copy on 7 Nov 2026.